iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products.
| Website: | www.biospace.com |
| Email: | ir@ibioinc.com |
| Main Phone: | +1 302 355-0650 |
| Address: | 600 Madison Avenue |
| Address 2: | Suite 1601 |
| State: | NY |
| City / Town: | New York |
| Country: | US |
| Postal Code: | 10022-1737 |
| Exchange: | AMX |
| CEO: | Thomas F. Isett |
| Employees: | 55 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Ebola paranoia is spreading the country. At least, it’s spreading a lot faster than the actual Ebola virus, which is still limited to two total cases in the United States. Cable news
Stronger-than-expected consumer optimism and impressive earnings from major industrials led stocks to multi-year highs today. The Dow Jones Industrial Average rocketed 115.49 points, or 0.93
iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products.
| Website: | www.biospace.com |
| Email: | ir@ibioinc.com |
| Main Phone: | +1 302 355-0650 |
| Address: | 600 Madison Avenue |
| Address 2: | Suite 1601 |
| State: | NY |
| City / Town: | New York |
| Country: | US |
| Postal Code: | 10022-1737 |
| Exchange: | AMX |
| CEO: | Thomas F. Isett |
| Employees: | 55 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Ebola paranoia is spreading the country. At least, it’s spreading a lot faster than the actual Ebola virus, which is still limited to two total cases in the United States. Cable news
Stronger-than-expected consumer optimism and impressive earnings from major industrials led stocks to multi-year highs today. The Dow Jones Industrial Average rocketed 115.49 points, or 0.93
| Last Price 2.43 | Change $ -0.03 | Change % -1.22 | Tick N/A |
| Bid 2.35 | Bid Size 1,500.00 | Ask 2.38 | Ask Size 3,500.00 |
| Open 2.41 | High 2.44 | Low 2.32 | Prev Close 2.46 |
| Last Trade | Volume 10 mi | 52 Wk Hi 7.45 | 52 Wk Low 0.05 |
| Market Cap 423.8 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 174,415,206.00 | EPS (TTM) -1.19 | PE Ratio N/A | Exchange NYSE American |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 0 |
| Number of Buys | 0 | 0 |
| Number of Sells | 0 | 0 |
| Net Activity | 0 | 0 |
| Last 10 Buys | Shares |
|---|---|
| John D. McKey | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| John D. McKey | 1,000 |
| John D. McKey | 1,000 |
| John D. McKey | 1,000 |
| John D. McKey | 1,000 |
| John D. McKey | 1,000 |
| John D. McKey | 1,000 |
| John D. McKey | 1,000 |
| John D. McKey | 1,000 |
| John D. McKey | 1,000 |
| John D. McKey | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 3 | 3 | 3 | 3 |
| Low Target Price Estimate | 3 | 3 | 3 | 3 |
| Mean Target Price Estimate | 3 | 3 | 3 | 3 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 02/19/13 | 02/19/13 | 02/19/13 | 02/19/13 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| FWP | Free Writing Prospectus | 24 | 2018-06-13 |
| S-1/A | Amendment to general form for registration of securities under the Securities Act of 1933 | 73 | 2018-06-11 |
| 8-K | Report of unscheduled material events or corporate changes. | 6 | 2018-06-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-06-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-05-31 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 58 | 2018-05-11 |
| S-1 | General form for registration of securities under the Securities Act of 1933 | 91 | 2018-05-02 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-04-25 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 23 | 2018-04-03 |
| PRE 14A | Preliminary proxy statement providing notification matters to be brought to a vote | 23 | 2018-03-21 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 0 | 0 | 0 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait